IPAX-1 published in Neuro-Oncology Advances

ARTMS - Expand Your Reach TODAY

ARTMS - Expand Your Reach

Brain Tumor Imaging Using Amino Acid PET

Telix at ANZSNM ASM 2024

ProstACT GLOBAL Explained | Prostate Cancer Therapy Phase III Clinical Trial

Closing the Gap | Understanding inequities in prostate cancer care with Pete Tually

Closing the Gap | Understanding inequities in prostate cancer care with Professor Jeff Dunn AO

Telix at ANZSNM 2023

ZIRCON Phase III Study of TLX250-CDx in Clear Cell Renal Cell Carcinoma (ccRCC)

Telix Pharmaceuticals | Precision Oncology | See it. Treat it.

Larry’s Story | The first American man to be scanned with Telix's approved imaging agent.

TRALA Study of TLX66 in AL-Amyloidosis Presented at ASH 2021

Cyclotron extraction and dismantling by SCK CEN

First Cyclotron Removed from Seneffe Production Facility by SCK CEN

Telix Presentation at Kanazawa Uni Press Meeting for Prostate Cancer Imaging Study, 15 March 2021

Imaging and Robotics in Surgery (IRiS) Alliance

Telix Pharmaceuticals Limited - Edison Open House Presentation, January 2021

SNMMI Mid-winter Symposium: PSMA-11: Advances in Technology, Demand & Supply.

New Perspectives in Prostate and Kidney Cancer - Laura Ravasi, MD PhD

68Ga-PSMA-11: The PET/CT imaging tracer that changed the management of prostate cancer - Dr. Yong Du

Realizing the Promise of Nuclear Medicine in Oncology Theranostics - Prof. Oliver Sartor

Unmet Needs in RCC: ZIRCON Trial - Prof. Dr. Peter Mulders

Immuno-PET using 89Zr-labeled antibodies - Prof. Françoise Kraeber-Bodéré

PSMA Imaging Current Status and Prospects | SNMMI Annual Meeting 2020 | Telix Pharmaceuticals

Welcome to Telix Pharmaceuticals - Dr. Christian Behrenbruch and Dr. Andreas Kluge (Co-Founders)

TLX101 - Glioblastoma

Telix Pharmaceuticals Limited Corporate Video